BIS defines zero-tariff specialty pharmaceuticals and eligible jurisdictions under Proclamation 11020

BIS issued a notice defining the pharmaceutical products and listing the jurisdictions eligible for a zero ad valorem Section 232 tariff rate under Proclamation 11020 of April 2, 2026, covering orphan-indication drugs and associated ingredients, nuclear medicines, plasma derived therapies, fertility drugs, cell therapy products, gene therapy products, antibody drug conjugates, chemical, biological, radiological and nuclear medical countermeasures, and animal health. Products and associated ingredients receive the zero rate if they are of a jurisdiction with a current or forthcoming trade and security framework agreement or meet an urgent U.S. health need.